National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. NICE guideline NG161. 2020. (accessed 17 May 2020)

GP urgent cancer referrals decline by more than 70% as ‘fewer patients come forward’. 2020. (accessed 17 May 2020)

COVID-19 and cancer care

28 May 2020
3 min read
Volume 29 · Issue 10

We are living in virtually unprecedented times—‘virtually’ because pandemics have happened before, notably the ‘Spanish’ flu of 1918. The effects of the COVID-19 pandemic have been magnified by its enormous impact on the way people live their lives. We are used to being cushioned from the effects of disease as a natural catastrophe—at least in Western societies—but the current situation has changed this.

My specialty has been profoundly affected by the pandemic. In nearly 30 years as an oncology nurse, I have seen systemic anticancer treatments become more sophisticated. In the past 5 years, novel immunotherapy agents have offered patients with previously extremely poor prognoses renewed hope of extended, good quality lives. In the UK, patients have been encouraged to present to their GPs early with symptoms and there is a 28-day cancer target and investment in diagnostic capability. The pandemic has meant a huge reduction in patients presenting to GPs, leading to fewer urgent referrals (Philpotts, 2020).

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content